Swedish Orphan Biovitrum AB (Sobi) has appointed Anton Hoos to lead research and development and medical affairs at the company following the retirement of Anders Ullman. Dr Hoos will be based in Basel, Switzerland and report to chief executive Guido Oelkers. Sobi’s headquarters is in Stockholm, Sweden. Dr Hoos was most recently chief medical officer at Genomics Plc. He has also held senior positions at Amgen Inc and GSK Plc. He is currently a member of the board of the non-profit organisation Patient Focused Medicine Development, which he co-founded to involve patients in drug development. He received his medical degree from the Technical University of Munich in Germany.
Sobi announced the appointment on 2 February 2023.
Copyright 2023 Evernow Publishing Ltd